Jaroslav Žák

Scripps Research Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index1.1kcitations58works6.82yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Epigenetics and DNA Methylation(16), Immune Cell Function and Interaction(13), Cancer Immunotherapy and Biomarkers(9), Renal and related cancers(9), CAR-T cell therapy research(7)

Publications58 total

833 Sialic acid decouples T cell proliferation from differentiation through engagement of cellular stress response

Regular and Young Investigator Award Abstracts·2025Open Access

Positive and negative roles of myeloid cells in cancer immunotherapy

1 cited

Journal for ImmunoTherapy of Cancer·2025· 1 citedOpen Access

Catalyzing computational biology research at an academic institute through an interest network

PLoS Computational Biology·2025Open Access

Abstract 7288: Targeted degradation of mobile immune checkpoints to advance cancer therapy

Cancer Research·2025

Angioedema caused by of C1 esterase inhibitor deficiency

Vnitřní lékařství·2025Open Access

Figure S8 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

2025Open Access

Figure S6 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

2025Open Access

Figure S7 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

2025Open Access

Figure S11 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

2025Open Access

Figure S4 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

2025Open Access

Figure S14 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

2025Open Access

Figure S1 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

2025Open Access

Data from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

2025Open Access

Figure S3 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

2025Open Access

Figure S5 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

2025Open Access

Figure S13 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

2025Open Access

Figure S2 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

2025Open Access

Figure S12 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

2025Open Access

Figure S9 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

2025Open Access

Figure S10 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy

2025Open Access

page 1 of 3Next →

Frequent Co-authors

John R. Teijaro(33), Isaraphorn Pratumchai(22), Yingqin Hou(19), Peng Wu(18), Ke Qin(14), Brandon Dinner(13), Evan W. Weber(13), Yujie Shi(12), Wenjian Wang(12), Xin Lü(8), Zhe Huang(8), Michael B. A. Oldstone(6), Judith A. Varner(6), Brett S. Marro(5), Namir Shaabani(5), Veronika Bachanová(4), Vincent F. Vartabedian(4), Nhan Nguyen(4), Yujie Shi(4), Kristi Marquardt(3)